10 RESULTS
COMMENT Our lab (Dodart et al, 2005) first showed that intra-parenchymal lentiviral delivery of apoE2 reduces brain amyloid burden in APP transgenic mice, and over a relatively short period of time. We, together with the Crystal laboratory (Zhao et al. 2016), sub
COMMENT The choice of dose requires both a dose-ranging safety assessment (done with both single and multiple doses in Phase 1) and some reasonably definitive measure of efficacy (usually accomplished by dose-ranging studies in Phase 2, and not usually done in Ph
COMMENT Drugs of course fail for many reasons—wrong mechanism, wrong target, wrong patient population, wrong dose, etc. In the case of solanezumab, if one accepts that the drug was "active," albeit with a very modest effect size (an assumption I share b
COMMENT I first met Allen way back in 1976 while considering a residency in neurology at Duke. He was as brilliant, engaging, and provocative then as he was during our last meeting a few years ago. I think Allen enjoyed being outside the mainstream scientifically
COMMENT The paper is very interesting and further supports an important role for microglia in AD pathology. Here it appears that adaptive immunity (e.g., B-cell-derived antibodies) stimulates microglial phagocytosis/clearance of Aβ/amyloid in the mouse brain. Thi
COMMENT thoughtful comments. I'd like to underscore that we are not stating that anti-tau monoclonal antibodies
COMMENT The paper by Hudry et al. is a beautiful extension of a paper my lab published almost nine years ago using viral vectors to deliver ApoE isoforms to the brains of PDAPP mice (see Dodart et al., 2005). In our study we showed that direct intrahippocampal ad
COMMENT Excellent summary of current knowledge. As to the initiating factors, I believe there is evidence for an entero-hepatic-immunological axis as the major generator of both nitrosative/oxidative stress and mitoenergetic stress in peripheral tissues, which ef
COMMENT PAUL_STEVEN_M 0 Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho.
COMMENT sink" should continue to be explored as a basis for therapy. 0 PAUL_STEVEN_M
